Lv52
1276 积分 2022-11-30 加入
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
1小时前
待确认
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
5天前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
5天前
已完结
Bullous pemphigoid
10天前
已完结
Allergic Rhinitis in China: Trends, Challenges and Implications Over the Past Two Decades
11天前
已完结
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
17天前
已关闭
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
18天前
已完结
CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-deleted Cancer
20天前
已完结
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
25天前
已关闭
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
25天前
已完结
皖公网安备34019202002308
